Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[MTX].

Yuko Kaneko

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |June 18, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Methotrexate (MTX) is a key rheumatoid arthritis (RA) drug, effective alone or with biologics. Further research is needed to determine optimal MTX dosing for maintaining remission while minimizing side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Patient reports of evaluations for interstitial lung disease in patients with connective tissue diseases and rheumatoid arthritis: an international survey.

    Respiratory research·2026
    Same author

    The progression of initial symptoms and its relationship with the clinical course in adult-onset Still's disease: from the KEIO-AOSD cohort.

    EULAR rheumatology open·2026
    Same author

    Difficult-to-treat or clinical inertia?: the importance of earnest shared decision making in the management of rheumatoid arthritis.

    EULAR rheumatology open·2026
    Same author

    Assessment of drug levels as a biomarker in rheumatoid arthritis.

    EULAR rheumatology open·2026
    Same author

    Achievement of intermediate treatment targets for Still's disease under tocilizumab treatment: a post-hoc analysis of the phase III trial.

    Immunological medicine·2026
    Same author

    2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management.

    International journal of rheumatic diseases·2026

    Area of Science:

    • Rheumatology
    • Pharmacology

    Context:

    • Methotrexate (MTX) is a cornerstone therapy for rheumatoid arthritis (RA).
    • MTX monotherapy demonstrates comparable efficacy to TNF inhibitors (TNFi) and can prevent joint destruction in early RA.
    • Combination therapy with MTX and TNFi offers superior outcomes compared to monotherapy.

    Purpose:

    • To evaluate the efficacy of methotrexate (MTX) in rheumatoid arthritis (RA) management.
    • To explore the role of MTX in combination with biological agents for inducing remission.
    • To investigate the potential for reducing MTX dosage once remission is achieved.

    Summary:

    • Methotrexate (MTX) is an effective anchor drug for rheumatoid arthritis (RA), with monotherapy showing efficacy comparable to TNF inhibitors (TNFi).
    • Combining MTX with TNFi or other biological agents significantly improves remission rates compared to monotherapy.

    Related Experiment Videos

  • Despite its benefits, MTX can cause adverse effects like hepatotoxicity and bone marrow suppression, raising questions about optimal maintenance dosing.

    • Impact:

    • MTX is crucial for managing RA, offering joint protection and improved remission rates, especially when combined with biologics.
    • Understanding optimal MTX dosing strategies is essential for balancing treatment efficacy and patient safety.
    • Further research into methotrexate's dosage and usage is required to refine rheumatoid arthritis treatment protocols.